Join the Glaucoma (Open Angle) group to help and get support from people like you.
Glaucoma (Open Angle) News
Drop in Mental Health Scores Seen With Primary Open-Angle Glaucoma Diagnosis
MONDAY, June 9, 2025 – Diagnosis of primary open-angle glaucoma (POAG) is associated with a reduction in mental health scores, according to a study published online June 5 in JAMA Ophthalmology. Mae...
Swept-Source Anterior Segment OCT Can Help Distinguish Early Childhood Glaucoma
FRIDAY, May 23, 2025 – The noninvasive swept-source anterior-segment optical coherence tomography (SS-ASOCT) can diagnose early-onset childhood glaucoma, according to a study published online May 22...
'Good' Cholesterol Could Be Bad For Glaucoma
WEDNESDAY, Feb. 5, 2025 – The cholesterol that’s good for your heart health might be bad for your eye health, and vice versa, a new study says. “Good” HDL cholesterol appears to increase risk of glau...
Elevated HDL Cholesterol Linked to Increased Risk for Glaucoma
WEDNESDAY, Feb. 5, 2025 – Elevated high-density lipoprotein cholesterol (HDL-C) is associated with an increased risk for glaucoma, while elevated low-density lipoprotein cholesterol (LDL-C), total...
1.5 Million U.S. Adults Have Vision-Affecting Glaucoma
FRIDAY, Oct. 18, 2024 – An estimated 2.56 percent of U.S. adults ages 40 years and older have glaucoma, according to a study published online Oct. 17 in JAMA Ophthalmology. Joshua R. Ehrlich, M.D., ...
FDA Approves iDose TR (travoprost intracameral implant) for the Treatment of Glaucoma
ALISO VIEJO, Calif.--(BUSINESS WIRE) December 14, 2023 – Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment...
FDA Approves Iyuzeh (latanoprost ophthalmic solution) for the Reduction of Elevated Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension
Iyuzeh™ (latanoprost ophthalmic solution) 0.005% is the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA) in the United States LE...
FDA Approves Omlonti (omidenepag isopropyl ophthalmic solution) for Reduction of Elevated Intraocular Pressure in Primary Open-Angle Glaucoma or Ocular Hypertension
EMERYVILLE, Calif. & UBE, Japan--(BUSINESS WIRE) September 26, 2022 --Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., Ltd. (Santen), and UBE Corporation (UBE) today announced that the...
FDA Approves Durysta (bimatoprost implant) to Lower Intraocular Pressure In Open-Angle Glaucoma or Ocular Hypertension Patients
DUBLIN, March 5, 2020 /PRNewswire/ – Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug...
FDA Approves Rocklatan (netarsudil and latanoprost ophthalmic solution) for the Reduction of Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension
DURHAM, N.C.--(BUSINESS WIRE)--Mar. 12, 2019-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development and...
FDA Approves Xelpros (latanoprost ophthalmic emulsion) to Treat Open-angle Glaucoma or Ocular Hypertension
MUMBAI, India & PRINCETON, N.J.--(BUSINESS WIRE) September 14, 2018 --Sun Pharmaceutical Industries Ltd. and Sun Pharma Advanced Research Company Ltd. (SPARC) today announced U.S. Food and Drug...
Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa (netarsudil ophthalmic solution) 0.02% for Patients with Open-Angle Glaucoma or Ocular Hypertension
IRVINE, Calif.--(BUSINESS WIRE)--Dec. 18, 2017-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), an ophthalmic pharmaceutical company focused on the discovery, development, and...
FDA Approves Vyzulta (latanoprostene bunod) Ophthalmic Solution for Open-Angle Glaucoma, Ocular Hypertension
LAVAL, Quebec and SOPHIA ANTIPOLIS, France, Nov. 2, 2017 /PRNewswire/ – Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) wholly owned subsidiary, Bausch + Lomb, a leading...
Alcon Announces FDA Approval of Simbrinza Suspension, a New Beta Blocker-Free, Fixed-Combination Therapy for Glaucoma Patients
Basel, April 19, 2013 – Alcon, the global leader in eye care and a division of Novartis, announces US FDA approval for Simbrinza Suspension, indicated for the reduction of elevated intraocular...
FDA Approves Zioptan (tafluprost ophthalmic solution), Merck's Once-Daily, Preservative-Free Ophthalmic Medication
WHITEHOUSE STATION, N.J., Feb. 13, 2012 – Merck, known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved Zioptan (tafluprost o...